Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

2(40.0%)

5Total

Phase 2(3)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05683548Unknown

Replicor Compassionate Access Program

Role: lead

NCT02876419Completed

A Long Term Follow-up Study of Patients From the REP 301 Protocol

Role: lead

NCT02565719Phase 2Completed

REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection

Role: lead

NCT02726789Phase 2Completed

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

Role: lead

NCT02233075Phase 2Completed

REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection

Role: lead

NCT02646189Phase 1Completed

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Role: lead

NCT02646163Phase 1Completed

Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients

Role: lead

All 7 trials loaded